AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 302 min read$ATR

What AptarGroup (ATR) Said on Its Q3 Earnings Call

AptarGroup (ATR) reported Q3 earnings, highlighting growth in beauty, closures, and pharma sectors. Beauty core sales rose 8%, while closures saw 11% growth. Pharma developments include collaborations and acquisitions. The company recorded a $61.2M charge related to its Russian subsidiary. ATR forecasted Q4 adjusted EPS of $1.39-$1.47, up 17% YoY. Full-year capex is expected at $260M-$280M. Virginie Maes will lead Aptar Pharma starting January 1.

Original reporting
finance.yahoo.com
Published Oct 30, 2026, 4:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 4:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What AptarGroup (ATR) Said on Its Q3 Earnings Call — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ATRBullishMed
01

Why it matters

The earnings release offers fresh data and forward guidance, creating a mixed signal for traders. Positive guidance may attract buyers, while the charge and margin pressure could deter them.

02

Market read

Primary earnings disclosure with new guidance and a material charge, affecting ATR and related pharma packaging peers.

03

What to watch

Potential impact of the Russian deconsolidation and upcoming capital expenditures on cash flow.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

AptarGroup (NYSE:ATR) reported its Q3 earnings, highlighted drug‑delivery collaborations, disclosed a $61.2M charge from Russian deconsolidation, and provided Q4 EPS guidance.

Company-level read

Ticker impact

$ATRBullishHigh confidence
Context

AptarGroup disclosed Q3 results, a $61.2M pre‑tax charge, free cash flow figures and Q4 adjusted EPS guidance of $1.39‑$1.47.

Expected impact

mixed outlook with potential modest upside if investors focus on guidance, but near‑term pressure from the charge.

Evidence & confidence

The earnings release provides fresh numbers and forward guidance, a primary disclosure that can move the stock. The charge is a negative, but the 17% EPS growth guidance is positive.

Market effects

Sector

Aptar's pharma and beauty segment performance may influence peers in drug‑delivery and consumer‑care packaging.

Regional

European and Asian pharma equipment suppliers could see sentiment spillover.

Global

Limited to specialty packaging and drug‑delivery markets.

Counterpoint

What could challenge this read

The $61M charge and margin compression could signal deeper operational issues, outweighing the modest guidance uplift.

Key entities

  • company
    AptarGroup

    US‑listed provider of dispensing and drug‑delivery systems.

  • partner
    Bausch + Lomb

    Collaborating on ophthalmic technology.

Read at source← All news

StoryAptarGroup posts Q3 2026 earnings beat with $1.52 adjusted EPS and 6% revenue growth

Also covered by

4 outlets

Related articles

OCT 31
$ATRMed

AptarGroup Inc (ATR) (Q3 2026) Earnings Call Highlights: Core Sales Grow 5% as Pharma

AptarGroup Inc (ATR) reported Q3 2026 core sales growth of 5% across all segments, with Pharma, Beauty, and Closures up 8%, 8%, and 11% respectively. Adjusted EPS was $1.52, down 6% YoY. Pharma growth was impacted by emergency medicine destocking, expected to affect full-year sales by $65M. Beauty and Closures margins declined due to operational challenges. CEO Gael Touya outlined plans for multi-year transformation in Beauty and reiterated long-term growth targets for Pharma.

finance.yahoo.com7 min
OCT 29
$ATRMedAI 8/10

AptarGroup Sales Rise 6%; Adjusted EPS Reaches $1.52

AptarGroup reported Q3 2026 sales of $1.02B, up 6% YoY, with adjusted EPS at $1.52. Core sales rose 5%, while net income fell to $32.6M from $127.9M YoY due to a $60.4M after-tax impact from deconsolidating its Russian subsidiary. CEO Gael Touya highlighted priorities including customer relationships and innovation.

tradingview.com1 min
OCT 29
$ATRMedAI 9/10

APTARGROUP, INC. (ATR): Aptar Reports Third Quarter 2026 Results

APTARGROUP, INC. (ATR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aptar Reports Third Quarter 2026 Results Crystal Lake, Illinois, October 29, 2026 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today reported the following third quarter results

SEC EDGAR 8-K7 min